Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
- Associated Therapies
- -
Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Western Regional Medical Center
- Registration Number
- NCT02408042
- Locations
- ๐บ๐ธ
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States
Stem Cell Transplantation for Stiff Person Syndrome (SPS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 23
- Registration Number
- NCT02282514
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
- First Posted Date
- 2014-08-25
- Last Posted Date
- 2023-03-10
- Target Recruit Count
- 18
- Registration Number
- NCT02224872
- Locations
- ๐บ๐ธ
The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
๐บ๐ธMedical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 6
- Registration Number
- NCT02212574
- Locations
- ๐บ๐ธ
Ann and Robert H Lurie Children's Hospital of Chicago Hematology/Oncology, Chicago, Illinois, United States
๐บ๐ธChildren's Hospital Colorado Center for Cancer & Blood Disorders, Aurora, Colorado, United States
๐บ๐ธNationwide Children's Hospital, Columbus, Ohio, United States
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02199041
- Locations
- ๐บ๐ธ
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
- First Posted Date
- 2014-06-19
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Rafic Farah, MD
- Target Recruit Count
- 28
- Registration Number
- NCT02167958
- Locations
- ๐บ๐ธ
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT02106988
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2018-09-24
- Target Recruit Count
- 4
- Registration Number
- NCT02029638
- Locations
- ๐บ๐ธ
Johns Hopkins University, Baltimore, Maryland, United States
Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 92
- Registration Number
- NCT01873326
- Locations
- ๐บ๐ธ
University of Southern California, Los Angeles, California, United States
๐บ๐ธStanford University Medical Center, Stanford, California, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 83
- Registration Number
- NCT01864109
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Commack, Commack, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.